Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

Julia J. Scialla, Wei Ling Lau, Muredach P. Reilly, Tamara Isakova, Hsueh Ying Yang, Matthew H. Crouthamel, Nicholas W. Chavkin, Mahboob Rahman, Patricia Wahl, Ansel P. Amaral, Takayuki Hamano, Stephen R. Master, Lisa Nessel, Boyang Chai, Dawei Xie, Radhakrishna R. Kallem, Jing Chen, James P. Lash, John W. Kusek, Matthew J. BudoffCecilia M. Giachelli, Myles Wolf

Research output: Contribution to journalArticle

Abstract

Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its role in arterial calcification is less clear. In order to study this, we quantified coronary artery and thoracic aorta calcium by computed tomography in 1501 patients from the Chronic Renal Insufficiency Cohort (CRIC) study within a median of 376 days (interquartile range 331-420 days) of baseline. Baseline plasma FGF23 was not associated with the prevalence or severity of coronary artery calcium after multivariable adjustment. In contrast, higher serum phosphate levels were associated with prevalence and severity of coronary artery calcium, even after adjustment for FGF23. Neither FGF23 nor serum phosphate were consistently associated with thoracic aorta calcium. We could not detect mRNA expression of FGF23 or its coreceptor, klotho, in human or mouse vascular smooth muscle cells, or normal or calcified mouse aorta. Whereas elevated phosphate concentrations induced calcification in vitro, FGF23 had no effect on phosphate uptake or phosphate-induced calcification regardless of phosphate concentration or even in the presence of soluble klotho. Thus, in contrast to serum phosphate, FGF23 is not associated with arterial calcification and does not promote calcification experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct mechanisms.

Original languageEnglish (US)
Pages (from-to)1159-1168
Number of pages10
JournalKidney International
Volume83
Issue number6
DOIs
StatePublished - Jun 2013
Externally publishedYes

Fingerprint

Phosphates
Calcium
Coronary Vessels
Thoracic Aorta
Chronic Renal Insufficiency
Cardiovascular Diseases
Serum
fibroblast growth factor 23
Left Ventricular Hypertrophy
Vascular Smooth Muscle
Smooth Muscle Myocytes
Aorta
Cohort Studies
Tomography
Messenger RNA

Keywords

  • Chronic kidney disease
  • Fibroblast growth factor 23
  • Phosphate
  • Vascular calcification
  • Vascular smooth muscle

ASJC Scopus subject areas

  • Nephrology

Cite this

Scialla, J. J., Lau, W. L., Reilly, M. P., Isakova, T., Yang, H. Y., Crouthamel, M. H., ... Wolf, M. (2013). Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International, 83(6), 1159-1168. https://doi.org/10.1038/ki.2013.3

Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. / Scialla, Julia J.; Lau, Wei Ling; Reilly, Muredach P.; Isakova, Tamara; Yang, Hsueh Ying; Crouthamel, Matthew H.; Chavkin, Nicholas W.; Rahman, Mahboob; Wahl, Patricia; Amaral, Ansel P.; Hamano, Takayuki; Master, Stephen R.; Nessel, Lisa; Chai, Boyang; Xie, Dawei; Kallem, Radhakrishna R.; Chen, Jing; Lash, James P.; Kusek, John W.; Budoff, Matthew J.; Giachelli, Cecilia M.; Wolf, Myles.

In: Kidney International, Vol. 83, No. 6, 06.2013, p. 1159-1168.

Research output: Contribution to journalArticle

Scialla, JJ, Lau, WL, Reilly, MP, Isakova, T, Yang, HY, Crouthamel, MH, Chavkin, NW, Rahman, M, Wahl, P, Amaral, AP, Hamano, T, Master, SR, Nessel, L, Chai, B, Xie, D, Kallem, RR, Chen, J, Lash, JP, Kusek, JW, Budoff, MJ, Giachelli, CM & Wolf, M 2013, 'Fibroblast growth factor 23 is not associated with and does not induce arterial calcification', Kidney International, vol. 83, no. 6, pp. 1159-1168. https://doi.org/10.1038/ki.2013.3
Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International. 2013 Jun;83(6):1159-1168. https://doi.org/10.1038/ki.2013.3
Scialla, Julia J. ; Lau, Wei Ling ; Reilly, Muredach P. ; Isakova, Tamara ; Yang, Hsueh Ying ; Crouthamel, Matthew H. ; Chavkin, Nicholas W. ; Rahman, Mahboob ; Wahl, Patricia ; Amaral, Ansel P. ; Hamano, Takayuki ; Master, Stephen R. ; Nessel, Lisa ; Chai, Boyang ; Xie, Dawei ; Kallem, Radhakrishna R. ; Chen, Jing ; Lash, James P. ; Kusek, John W. ; Budoff, Matthew J. ; Giachelli, Cecilia M. ; Wolf, Myles. / Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. In: Kidney International. 2013 ; Vol. 83, No. 6. pp. 1159-1168.
@article{422808adefd64928a9251e4ee0efa983,
title = "Fibroblast growth factor 23 is not associated with and does not induce arterial calcification",
abstract = "Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its role in arterial calcification is less clear. In order to study this, we quantified coronary artery and thoracic aorta calcium by computed tomography in 1501 patients from the Chronic Renal Insufficiency Cohort (CRIC) study within a median of 376 days (interquartile range 331-420 days) of baseline. Baseline plasma FGF23 was not associated with the prevalence or severity of coronary artery calcium after multivariable adjustment. In contrast, higher serum phosphate levels were associated with prevalence and severity of coronary artery calcium, even after adjustment for FGF23. Neither FGF23 nor serum phosphate were consistently associated with thoracic aorta calcium. We could not detect mRNA expression of FGF23 or its coreceptor, klotho, in human or mouse vascular smooth muscle cells, or normal or calcified mouse aorta. Whereas elevated phosphate concentrations induced calcification in vitro, FGF23 had no effect on phosphate uptake or phosphate-induced calcification regardless of phosphate concentration or even in the presence of soluble klotho. Thus, in contrast to serum phosphate, FGF23 is not associated with arterial calcification and does not promote calcification experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct mechanisms.",
keywords = "Chronic kidney disease, Fibroblast growth factor 23, Phosphate, Vascular calcification, Vascular smooth muscle",
author = "Scialla, {Julia J.} and Lau, {Wei Ling} and Reilly, {Muredach P.} and Tamara Isakova and Yang, {Hsueh Ying} and Crouthamel, {Matthew H.} and Chavkin, {Nicholas W.} and Mahboob Rahman and Patricia Wahl and Amaral, {Ansel P.} and Takayuki Hamano and Master, {Stephen R.} and Lisa Nessel and Boyang Chai and Dawei Xie and Kallem, {Radhakrishna R.} and Jing Chen and Lash, {James P.} and Kusek, {John W.} and Budoff, {Matthew J.} and Giachelli, {Cecilia M.} and Myles Wolf",
year = "2013",
month = "6",
doi = "10.1038/ki.2013.3",
language = "English (US)",
volume = "83",
pages = "1159--1168",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Fibroblast growth factor 23 is not associated with and does not induce arterial calcification

AU - Scialla, Julia J.

AU - Lau, Wei Ling

AU - Reilly, Muredach P.

AU - Isakova, Tamara

AU - Yang, Hsueh Ying

AU - Crouthamel, Matthew H.

AU - Chavkin, Nicholas W.

AU - Rahman, Mahboob

AU - Wahl, Patricia

AU - Amaral, Ansel P.

AU - Hamano, Takayuki

AU - Master, Stephen R.

AU - Nessel, Lisa

AU - Chai, Boyang

AU - Xie, Dawei

AU - Kallem, Radhakrishna R.

AU - Chen, Jing

AU - Lash, James P.

AU - Kusek, John W.

AU - Budoff, Matthew J.

AU - Giachelli, Cecilia M.

AU - Wolf, Myles

PY - 2013/6

Y1 - 2013/6

N2 - Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its role in arterial calcification is less clear. In order to study this, we quantified coronary artery and thoracic aorta calcium by computed tomography in 1501 patients from the Chronic Renal Insufficiency Cohort (CRIC) study within a median of 376 days (interquartile range 331-420 days) of baseline. Baseline plasma FGF23 was not associated with the prevalence or severity of coronary artery calcium after multivariable adjustment. In contrast, higher serum phosphate levels were associated with prevalence and severity of coronary artery calcium, even after adjustment for FGF23. Neither FGF23 nor serum phosphate were consistently associated with thoracic aorta calcium. We could not detect mRNA expression of FGF23 or its coreceptor, klotho, in human or mouse vascular smooth muscle cells, or normal or calcified mouse aorta. Whereas elevated phosphate concentrations induced calcification in vitro, FGF23 had no effect on phosphate uptake or phosphate-induced calcification regardless of phosphate concentration or even in the presence of soluble klotho. Thus, in contrast to serum phosphate, FGF23 is not associated with arterial calcification and does not promote calcification experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct mechanisms.

AB - Elevated fibroblast growth factor 23 (FGF23) is associated with cardiovascular disease in patients with chronic kidney disease. As a potential mediating mechanism, FGF23 induces left ventricular hypertrophy; however, its role in arterial calcification is less clear. In order to study this, we quantified coronary artery and thoracic aorta calcium by computed tomography in 1501 patients from the Chronic Renal Insufficiency Cohort (CRIC) study within a median of 376 days (interquartile range 331-420 days) of baseline. Baseline plasma FGF23 was not associated with the prevalence or severity of coronary artery calcium after multivariable adjustment. In contrast, higher serum phosphate levels were associated with prevalence and severity of coronary artery calcium, even after adjustment for FGF23. Neither FGF23 nor serum phosphate were consistently associated with thoracic aorta calcium. We could not detect mRNA expression of FGF23 or its coreceptor, klotho, in human or mouse vascular smooth muscle cells, or normal or calcified mouse aorta. Whereas elevated phosphate concentrations induced calcification in vitro, FGF23 had no effect on phosphate uptake or phosphate-induced calcification regardless of phosphate concentration or even in the presence of soluble klotho. Thus, in contrast to serum phosphate, FGF23 is not associated with arterial calcification and does not promote calcification experimentally. Hence, phosphate and FGF23 promote cardiovascular disease through distinct mechanisms.

KW - Chronic kidney disease

KW - Fibroblast growth factor 23

KW - Phosphate

KW - Vascular calcification

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=84882238083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882238083&partnerID=8YFLogxK

U2 - 10.1038/ki.2013.3

DO - 10.1038/ki.2013.3

M3 - Article

C2 - 23389416

AN - SCOPUS:84882238083

VL - 83

SP - 1159

EP - 1168

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -